Ascentage Pharma's Presentation at the ASH Annual Meeting
ROCKVILLE, Md. and SUZHOU, China — Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855), a notable player in the global biopharmaceutical sector, has made impressive strides in oncology treatments. The company's leading product, lisaftoclax (APG-2575), a Bcl-2 inhibitor, is at the forefront of its innovative approach. Recently, results from two comprehensive clinical studies were chosen for presentation at the esteemed 67th American Society of Hematology (ASH) Annual Meeting. This marks the fourth year in a row that lisaftoclax's clinical data has garnered attention at this significant event.
Advancements in Cancer Treatments
Ascentage Pharma has been forging ahead with the development of groundbreaking therapies aimed at addressing vital medical needs in cancer care. Lisaftoclax, which can be taken orally, has exhibited promising effects not only on hematologic malignancies but also on various solid tumors. The drug is already on the market in China, having received the necessary approvals to treat adult patients diagnosed with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously undergone at least one systemic therapy, including Bruton’s tyrosine kinase (BTK) inhibitors.
At the upcoming ASH Annual Meeting, Ascentage Pharma is set to present a detailed oral report regarding lifestoclax's latest findings from a Phase II study evaluating its effectiveness in relapsed/refractory (R/R) CLL/SLL. Additionally, the company plans to showcase data regarding the combination of lisaftoclax with azacitidine (AZA) for patients suffering from newly diagnosed or previously treated myeloid malignancies.
Key Highlights from the ASH 2025 Presentations
The ASH Annual Meeting is a significant event that unites hematology experts from across the globe, presenting the latest research findings on hematologic disorders. The 67th Annual Meeting is scheduled for December 6-9, 2025, and will take place both online and in person in Orlando, Florida. Numerous sessions will spotlight the advancements made by Ascentage Pharma and its innovative therapies.
Statements from Leadership
Dr. Yifan Zhai, the Chief Medical Officer of Ascentage Pharma, shared insights regarding the promising safety and efficacy profile of lisaftoclax across multiple studies. He emphasized, "Lisaftoclax has shown tangible results and safe usage patterns, reinforcing its potential in the treatment of hematologic disorders. We are excited to once again share these findings at ASH 2025, reflecting our commitment to advancing treatments that address unmet needs.”
Strategic Focus on Ongoing Clinical Trials
The company is actively involved in four global registrational Phase III studies. These trials include a focus on patients with different levels of treatment history, aiming to address recalcitrant cases of CLL/SLL. Ascentage is determined to accelerate its clinical development programs to enable patient access to new therapeutic options more swiftly.
Moreover, Ascentage’s robust pipeline features numerous investigational candidates, including olverembatinib and APG-5918, complementing its lead asset, lisaftoclax. Each of these candidates has been specifically engineered to tackle some of the most challenging cancer types with the potential for significant therapeutic impact.
Public interest in these findings is expected to grow as the ASH Conference approaches, providing a platform for global recognition of Ascentage Pharma's advancements in cancer therapeutics.
Frequently Asked Questions
What is the focus of Ascentage Pharma's presentation at ASH 2025?
Ascentage Pharma will present findings from two clinical studies on lisaftoclax, emphasizing its effectiveness for CLL/SLL and other myeloid malignancies.
What is lisaftoclax?
Lisaftoclax is an oral Bcl-2 inhibitor developed by Ascentage Pharma, currently approved in China for treating adult patients with chronic lymphocytic leukemia.
What are the future plans for Ascentage Pharma?
Ascentage Pharma aims to accelerate its clinical development programs and expand treatment options for patients, focusing on positive outcomes in ongoing global Phase III trials.
Who is Dr. Yifan Zhai?
Dr. Yifan Zhai is the Chief Medical Officer of Ascentage Pharma, spearheading the company's clinical research and development efforts.
Where can I learn more about Ascentage Pharma?
For further information, you can visit the company’s official website, which details their drug developments and upcoming initiatives.
